Clinical Trial News and Research

RSS

Kids with fluctuating gut microbiome show poorer growth

Malnutrition is a leading cause of death in children under age 5, and nearly 150 million children globally under this age have stunted growth from lack of nutrition.

9 Sep 2025

Simple support tools improve blood pressure management in hypertensive patients

For some patients struggling to control high blood pressure, something as simple as having blood pressure monitors at home and texted reminders to use them could be the key to stabilizing or even lowering their blood pressures, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania.

9 Sep 2025

Ketogenic diet shows promise in reducing depression symptoms in college students

A new study shows an association between at least 10 weeks of following a well-formulated ketogenic diet and a roughly 70% decrease in depression symptoms among a small group of college students.

9 Sep 2025

Experts review the evidence on coenzyme Q10 and cognitive decline

Researchers reviewed evidence on coenzyme Q10 (CoQ10) and cognition, finding strong biological support and positive results in animal models but mixed outcomes in human trials. Larger, high-quality studies are needed to clarify whether CoQ10 can protect against cognitive decline and neurodegenerative diseases.

9 Sep 2025

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S., launched an innovative national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.

9 Sep 2025

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

9 Sep 2025

LuCE study identifies key communication barriers between lung cancer patients and caregivers

A large-scale survey conducted by Lung Cancer Europe (LuCE) has identified critical communication barriers that affect information access, understanding, and shared decision-making among lung cancer patients and caregivers across Europe.

9 Sep 2025

Study highlights potential value of low-dose CT screening for lung cancer among Asian women

Results from the Female Asian Nonsmoker Screening Study (FANSS) highlight the potential value of low-dose CT (LDCT) screening for lung cancer among a growing but underserved population: Asian women with no history of smoking.

9 Sep 2025

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrates that monitoring circulating tumor DNA (ctDNA) can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC).

9 Sep 2025

Dengue infection leaves lasting genetic imprint on immunity

Just as a computer's operating system can be rewritten after a major update, dengue infection can 're-programme' the body's immune system, leaving a long-lasting genetic imprint that influences how people respond to future infections-an effect not seen with vaccination.

9 Sep 2025

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.

8 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

8 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

8 Sep 2025

New class of antihypertensive medications may have both kidney- and cardio-protective benefits

Adding the novel medication baxdrostat to standard care may help manage high blood pressure and delay the progression of kidney disease in people with chronic kidney disease and uncontrolled high blood pressure , according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025.

8 Sep 2025

New hydrogel may help alleviate negative impacts of menopause

A new hydrogel applied directly to vaginal tissues may help alleviate the negative impacts of menopause, according to a new study from scientists at the University of California San Diego.

8 Sep 2025

Study tests the feasibility of drone-delivered AEDs for out-of-hospital cardiac arrest

In the UK there are more than 40,000 out-of-hospital cardiac arrests (OHCA) annually, but fewer than 10% of people survive.

8 Sep 2025

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

8 Sep 2025

Previous
1
...
51
52
53
54
55
56
57
...
1183
Next

Clinical Trial News and Research

Kids with fluctuating gut microbiome show poorer growth

Simple support tools improve blood pressure management in hypertensive patients

Ketogenic diet shows promise in reducing depression symptoms in college students

Experts review the evidence on coenzyme Q10 and cognitive decline

City of Hope launches innovative national clinical trials model to expand access to cancer treatments

IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer

LuCE study identifies key communication barriers between lung cancer patients and caregivers

Study highlights potential value of low-dose CT screening for lung cancer among Asian women

Monitoring ctDNA can personalize the use of consolidation immunotherapy in patients with LS-SCLC

Dengue infection leaves lasting genetic imprint on immunity

New strategy for difficult-to-treat mesothelioma: Immunotherapy and ctDNA insights

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Ifinatamab deruxtecan may benefit patients with recurrent or progressive ES-SCLC

New class of antihypertensive medications may have both kidney- and cardio-protective benefits

New hydrogel may help alleviate negative impacts of menopause

Study tests the feasibility of drone-delivered AEDs for out-of-hospital cardiac arrest

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Metabolomics

Improve fermentation and cell culture performance with real-time gas analysis

Scaling patient-derived organoid research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer